Nektar Therapeutics (NKTR) Revenue (2010 - 2026)

Nektar Therapeutics' Revenue history runs 17 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Revenue rose 3.83% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $55.6 million (down 36.24% YoY), while the FY2025 annual figure was $55.2 million, down 43.89% from the prior year.
• Revenue was $10.9 million for Q1 2026 at Nektar Therapeutics, down from $21.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $29.2 million in Q4 2024 to a low of $10.5 million in Q1 2025.
• Historically, Revenue has averaged $20.4 million across 5 years, with a median of $21.8 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Revenue grew 22.15% in 2024, then slumped 52.42% in 2025.
• A 5-year view of Revenue shows it stood at $22.0 million in 2022, then increased by 8.45% to $23.9 million in 2023, then grew by 22.15% to $29.2 million in 2024, then dropped by 25.25% to $21.8 million in 2025, then slumped by 50.19% to $10.9 million in 2026.
• The last three Revenue figures came in at $10.9 million (Q1 2026), $21.8 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.